MMP9 and rheumatoid arthritis: Andecaliximab, a recombinant IgG4 monoclonal antibody targeting MMP9, is under development for the treatment different types of diseases, such as rheumatoid arthritis, Crohn’s disease, and non-small cell lung cancer (Gossage et al., 2018; Schreiber et al., 2018).